I was at an event with a group of MBA students a couple of weeks ago, chatting with two of them. One asked me how the venture deal flow was different in the past. I made the off-hand comment that the World of Could seemed to have grown much bigger, but the World of Should hadn’t kept pace. That passing comment has stimulated a lot of thought on my part in the past couple of weeks. . . .
→ Read full post: Musing on the “World of Could” and the “World of Should”
|
||
|
October 2010 source: Medical Device & Diagnostic Industry online The MX Q&A: Ted Driscoll, Claremont Creek Ventures Fledgling device companies can get a leg up with VC firms by developing a product that is ‘unique and protectable,’ says Tibion’s anchor investor. The cofounders of Tibion Bionic Technologies may want to send a thank-you note to Will Smith for helping their start-up get off on the right foot in 2004. Ted Driscoll, a . . . What a difference a year makes. In 2009, with the nation’s economic storm raging with gale-force winds, most venture capitalists pulled in their horns, trimmed the size of their startup portfolios and only rarely invested in new startups, whether they were promising or not. When they did invest, it was mostly in later-stage rounds. Some pundits contend there is sizable surplus of early-stage capital today. True or not, this belief would never have been uttered earlier . . . |
||
|
© Claremont Creek 2012 |
||
